Skip to main content

Table 2 Clinical measures

From: The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsive disorder: a randomized, double-blind, sham-controlled, clinical trial

  tDCS (n = 28) Control (n = 30) ANOVA (time) ANOVA (time*group) ANOVA (group)
Baseline S12 S24 M1 Baseline S12 S24 M1
Y-BOCS total 29.8 ± 6.6 25.0 ± 8.2 21.7 ± 9.5 22.9 ± 10.0 28.1 ± 5.7 24.8 ± 7.1 22.4 ± 8.9 21.9 ± 10.3 F(1.85) = 30.83; P < 0.001 F(1.85) = 0.86; P = 0.420 F(1.00) = 0.07; P = 0.799
Y-BOCS obsession 15.2 ± 3.7 14.1 ± 3.5 11.1 ± 4.6 11.5 ± 5.0 14.1 ± 3.5 12.3 ± 4.4 11.1 ± 4.5 11.3 ± 5.4 F(2.23) = 25.01; P < 0.001 F(1.85) = 0.68; P = 0.523 F(1.00) = 0.10; P = 0.748
Y-BOCS compulsion 14.3 ± 3.7 12.5 ± 4.8 11.7 ± 8.7 11.4 ± 5.3 14.0 ± 3.1 12.5 ± 3.7 11.3 ± 5.0 10.6 ± 5.5 F(2.06) = 10.81; P < 0.001 F(2.06) = 0.147; P = 0.869 F(1.00) = 0.10; P = 0.748
  1. Y-BOCS Yale–Brown Obsessive and Compulsive Scale; S12 session 12; S24 session 24; M1 1 month after the last session